myositis ossificans
myositis ossificans
Explore linked clinical trials. Standard reference: MONDO:00039648 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, Ossification, Heterotopic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, connective tissue disorder, cutaneous mucinosis, fibrodysplasia ossificans progressiva, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 4, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans | Not yet recruiting | Phase 3 | 2026-10-08 | NCT07559513 | |
| A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP) | fibrodysplasia ossificans progressiva, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans | Recruiting | Not stated | 2026-10-01 | NCT06089616 | |
| Saracatinib Trial TO Prevent FOP | fibrodysplasia ossificans progressiva, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans | Active, not recruiting | Phase 2 | 2026-09-02 | NCT04307953 | |
| IL1 Inhibition in FOP | Ossification, Heterotopic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans | Recruiting | Not stated | 2026-08-06 | NCT06724562 | |
| A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Ossification, Heterotopic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fibrodysplasia ossificans progressiva, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans | Active, not recruiting | Phase 3 | 2026-07-17 | NCT05394116 | |
| To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | Ossification, Heterotopic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans | Recruiting | Phase 2 | 2026-05-22 | NCT05090891 | |
| The Fibrodysplasia Ossificans Progressiva (FOP) Registry | Bone Diseases, Developmental, Foot Deformities, Hallux Valgus, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Ossification, Heterotopic, Osteochondroma, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone disorder, connective tissue neoplasm, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans, neoplasm, osteochondrodysplasia | Recruiting | Not stated | 2026-04-08 | NCT02745158 | |
| A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Foot Deformities, Hallux Valgus, Inflammation, Ossification, Heterotopic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fibrodysplasia ossificans progressiva, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 2 / Phase 3 | 2025-10-14 | NCT06508021 |